Correction to: Where do university graduates live? – a computer vision approach using satellite images

Applied Intelligence - A Correction to this paper has been published: https://doi.org/10.1007/s10489-021-02433-z     

Traditional organizations and crisis management in transition—Organizational perspectives on new dynamics of independent civil engagement

Digitalization and the trend towards more short‐term and project‐oriented social engagement have had a direct impact on traditional crisis management. This societal change has supported the evolution of new types of volunteers who use low‐threshold potentials to organize and maintain support independently. Traditional institutions like the German Red Cross are challenged to deal with these rapid changes regarding their own organizational culture in relation to the new phenomenon of so‐called unaffiliated volunteers. This paper investigates how unaffiliated volunteers influence and change the organizational culture of German disaster management by analysing and reflecting organizational adaptation processes in the aftermath of the German floods in 2013, the storm events in the west of Germany in 2014 and the refugee relief mission in 2015–2016. Therefore, semi‐structured interviews with experts of the German Red Cross were held to analyse their reactions towards unaffiliated Volunteers during the Floods in 2013 and the refugee relief missions, and further focus group interviews were conducted to validate the extracted results. Findings suggest that among professionals and leading entities in the German Red Cross, a process of rethinking has emerged, recognizing the importance and necessity to open up organizational structures for the collaboration and coordination of unaffiliated volunteers.     

State-of-the-art of long-term preservation in product lifecycle management

Providing access to digital information for the indefinite future is the intention of long-term digital preservation systems. One application domain that certainly needs to implement such long-term digital preservation processes is the design and engineering industry. In this industry, products are designed, manufactured, and operated with the help of sophisticated software tools provided by product lifecycle management (PLM) systems. During all PLM phases, including geographically distributed cross-domain and cross-company collaboration, a huge amount of heterogeneous digital product data and metadata is created. Legal and economic requirements demand that this product data has to be archived and preserved for a long-time period. Unfortunately, the software that is able to interpret the data will become obsolete earlier than the data since the software and hardware lifecycle is relatively short-lived compared to a product lifecycle. Companies in the engineering industry begin to realize that their data is in danger of becoming unusable while the products are in operation for several decades. To address this issue, different academic and industrial initiatives have been initiated that try to solve this problem. This article provides an overview of these projects including their motivations, identified problems, and proposed solutions. The studied projects are also verified against a classification of important aspects regarding scope and functionality of digital preservation in the engineering industry. Finally, future research topics are identified.     

The residue of vector sets with applications to decidability problems in Petri nets

Summary A set K of integer vectors is called right-closed, if for any elementmK all vectors mm are also contained in K. In such a case K is a semilinear set of vectors having a minimal generating set res(K), called the residue of K. A general method is given for computing the residue set of a right-closed set, provided it satisfies a certain decidability criterion.Various right-closed sets wich are important for analyzing, constructing, or controlling Petri nets are studied. One such set is the set CONTINUAL(T) of all such markings which have an infinite continuation using each transition infinitely many times. It is shown that the residue set of CONTINUAL(T) can be constructed effectively, solving an open problem of Schroff. The proof also solves problem 24 (iii) in the EATCS-Bulletin. The new methods developed in this paper can also be used to show that it is decidable, whether a signal net is prompt [23] and whether certain -languages of a Petri net are empty or not.It is shown, how the behaviour of a given Petri net can be controlled in a simple way in order to realize its maximal central subbehaviour, thereby solving a problem of Nivat and Arnold, or its maximal live subbehaviour as well. This latter approach is used to give a new solution for the bankers problem described by Dijkstra.Since the restriction imposed on a Petri net by a fact [11] can be formulated as a right closed set, our method also gives a new general approach for implementations of facts.     

Altered mRNA and Protein Expression of Monocarboxylate Transporter MCT1 in the Cerebral Cortex and Cerebellum of Prion Protein Knockout Mice

The effect of a cellular prion protein (PrP^c) deficiency on neuroenergetics was primarily analyzed via surveying the expression of genes specifically involved in lactate/pyruvate metabolism, such as monocarboxylate transporters (MCT1, MCT2, MCT4). The aim of the present study was to elucidate a potential involvement of PrP^c in the regulation of energy metabolism in different brain regions. By using quantitative real-time polymerase chain reaction (qRT-PCR), we observed a marked reduction in MCT1 mRNA expression in the cortex of symptomatic Zürich I Prnp^−/− mice, as compared to their wild-type (WT) counterparts. MCT1 downregulation in the cortex was accompanied with significantly decreased expression of the MCT1 functional interplayer, the Na⁺/K⁺ ATPase α2 subunit. Conversely, the MCT1 mRNA level was significantly raised in the cerebellum of Prnp^−/− vs. WT control group, without a substantial change in the Na⁺/K⁺ ATPase α2 subunit expression. To validate the observed mRNA findings, we confirmed the observed change in MCT1 mRNA expression level in the cortex at the protein level. MCT4, highly expressed in tissues that rely on glycolysis as an energy source, exhibited a significant reduction in the hippocampus of Prnp^−/− vs. WT mice. The present study demonstrates that a lack of PrP^c leads to altered MCT1 and MCT4 mRNA/protein expression in different brain regions of Prnp^−/− vs. WT mice. Our findings provide evidence that PrP^c might affect the monocarboxylate intercellular transport, which needs to be confirmed in further studies.     

Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells

The development of nanocarriers (NC) for biomedical applications has gained large interest due to their potential to co-deliver drugs in a cell-type-targeting manner. However, depending on their surface characteristics, NC accumulate serum factors, termed protein corona, which may affect their cellular binding. We have previously shown that NC coated with carbohydrates to enable biocompatibility triggered the lectin-dependent complement pathway, resulting in enhanced binding to B cells via complement receptor (CR)1/2. Here we show that such NC also engaged all types of splenic leukocytes known to express CR3 at a high rate when NC were pre-incubated with native mouse serum resulting in complement opsonization. By focusing on dendritic cells (DC) as an important antigen-presenting cell type, we show that CR3 was essential for binding/uptake of complement-opsonized NC, whereas CR4, which in mouse is specifically expressed by DC, played no role. Further, a minor B cell subpopulation (B-1), which is important for first-line pathogen responses, and co-expressed CR1/2 and CR3, in general, engaged NC to a much higher extent than normal B cells. Here, we identified CR-1/2 as necessary for binding of complement-opsonized NC, whereas CR3 was dispensable. Interestingly, the binding of complement-opsonized NC to both DC and B-1 cells affected the expression of activation markers. Our findings may have important implications for the design of nano-vaccines against infectious diseases, which codeliver pathogen-specific protein antigen and adjuvant, aimed to induce a broad adaptive cellular and humoral immune response by inducing cytotoxic T lymphocytes that kill infected cells and pathogen-neutralizing antibodies, respectively. Decoration of nano-vaccines either with carbohydrates to trigger complement activation in vivo or with active complement may result in concomitant targeting of DC and B cells and thereby may strongly enhance the extent of dual cellular/humoral immune responses.     

Accurate Receptor-Ligand Binding Free Energies from Fast QM Conformational Chemical Space Sampling

Small molecule receptor-binding is dominated by weak, non-covalent interactions such as van-der-Waals hydrogen bonding or electrostatics. Calculating these non-covalent ligand-receptor interactions is a challenge to computational means in terms of accuracy and efficacy since the ligand may bind in a number of thermally accessible conformations. The conformational rotamer ensemble sampling tool (CREST) uses an iterative scheme to efficiently sample the conformational space and calculates energies using the semi-empirical ‘Geometry, Frequency, Noncovalent, eXtended Tight Binding’ (GFN2-xTB) method. This combined approach is applied to blind predictions of the modes and free energies of binding for a set of 10 drug molecule ligands to the cucurbit[n]urils CB[8] receptor from the recent ‘Statistical Assessment of the Modeling of Proteins and Ligands’ (SAMPL) challenge including morphine, hydromorphine, cocaine, fentanyl, and ketamine. For each system, the conformational space was sufficiently sampled for the free ligand and the ligand-receptor complexes using the quantum chemical Hamiltonian. A multitude of structures makes up the final conformer-rotamer ensemble, for which then free energies of binding are calculated. For those large and complex molecules, the results are in good agreement with experimental values with a mean error of 3 kcal/mol. The GFN2-xTB energies of binding are validated by advanced density functional theory calculations and found to be in good agreement. The efficacy of the automated QM sampling workflow allows the extension towards other complex molecular interaction scenarios.     

Continuous size fractionation of magnetic nanoparticles by using simulated moving bed chromatography

The size fractionation of magnetic nanoparticles is a technical problem, which until today can only be solved with great effort. Nevertheless, there is an important demand for nanoparticles with sharp size distributions, for example for medical technology or sensor technology. Using magnetic chromatography, we show a promising method for fractionation of magnetic nanoparticles with respect to their size and/or magnetic properties. This was achieved by passing magnetic nanoparticles through a packed bed of fine steel spheres with which they interact magnetically because single domain ferro-/ferrimagnetic nanoparticles show a spontaneous magnetization. Since the strength of this interaction is related to particle size, the principle is suitable for size fractionation. This concept was transferred into a continuous process in this work using a so-called simulated moving bed chromatography. Applying a suspension of magnetic nanoparticles within a size range from 20 to 120 nm, the process showed a separation sharpness of up to 0.52 with recovery rates of 100%. The continuous feed stream of magnetic nanoparticles could be fractionated with a space-time-yield of up to 5 mg/(L∙min). Due to the easy scalability of continuous chromatography, the process is a promising approach for the efficient fractionation of industrially relevant amounts of magnetic nanoparticles.     

Interleukin 6 and Aneurysmal Subarachnoid Hemorrhage. A Narrative Review

Interleukin 6 (IL-6) is a prominent proinflammatory cytokine. Neuroinflammation in general, and IL-6 signaling in particular, appear to play a major role in the pathobiology and pathophysiology of aneurysm formation and aneurysmal subarachnoid hemorrhage (SAH). Most importantly, elevated IL-6 CSF (rather than serum) levels appear to correlate with delayed cerebral ischemia (DCI, “vasospasm”) and secondary (“vasospastic”) infarctions. IL-6 CSF levels may also reflect other forms of injury to the brain following SAH, i.e., early brain damage and septic complications of SAH and aneurysm treatment. This would explain why many researchers have found an association between IL-6 levels and patient outcomes. These findings clearly suggest CSF IL-6 as a candidate biomarker in SAH patients. However, at this point, discrepant findings in variable study settings, as well as timing and other issues, e.g., defining proper clinical endpoints (i.e., secondary clinical deterioration vs. angiographic vasospasm vs. secondary vasospastic infarct) do not allow for its routine use. It is also tempting to speculate about potential therapeutic measures targeting elevated IL-6 CSF levels and neuroinflammation in SAH patients. Corticosteroids and anti-platelet drugs are indeed used in many SAH cases (not necessarily with the intention to interfere with detrimental inflammatory signaling), however, no convincing benefit has been demonstrated yet. The lack of a robust clinical perspective against the background of a relatively large body of data linking IL-6 and neuroinflammation with the pathophysiology of SAH is somewhat disappointing. One underlying reason might be that most relevant studies only report correlative data. The specific molecular pathways behind elevated IL-6 levels in SAH patients and their various interactions still remain to be delineated. We are optimistic that future research in this field will result in a better understanding of the role of neuroinflammation in the pathophysiology of SAH, which in turn, will translate into the identification of suitable biomarkers and even potential therapeutic targets.